Market Overview

XenoPort Shares Plunge On Negative Phase IIb Study

Shares of XenoPort (NASDAQ: XNPT) have plunged on negative Phase IIb study.

The Santa Clara, California-based developer, along with GlaxoSmithKline (NYSE: GSK), said that a Phase IIb study for gabapentin enacarbil failed to “demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches."

XNPT’s shares plunged 27.28% to $6.45 at 9:45 am EDT.

Read more from Benzinga's Company news.

Learn how to find the best stocks to trade each day in our 70 page E-Book and 90 minute online video for free.

Posted-In: movers and shakersNews Short Ideas Intraday Update Markets Trading Ideas

 

Related Articles (XNPT + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters